Investors
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
press release
August 7, 2017
Geneva, Switzerland and Boston, MA – 07 August, 2017 – ObsEva SA (NASDAQ: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics…
Read morepress release
June 29, 2017
Phase 2 nolasiban previously reported data supports potential for meaningfully increasing live birth rates in ART Non-clinical results of OBE022…
Read morepress release
June 7, 2017
– OBE2109 is a GnRH receptor antagonist currently in development as both a stand-alone treatment and with add-back therapy designed…
Read moreJune 29, 2023
May 18, 2022
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listing
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 –…
Read moreMedia
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840